National Center

7272 Greenville Avenue

Dallas, Texas 75231-4596

Tel 214 373 6300

http://www.americanheart.org

Asst. U.S. Attorney General

Department of Justice, Antitrust Division

950 Pennsylvania Avenue

Room 3109

Washington, D.C. 20530

Re: Business Review Request of the American Heart Association Pharmaceutical Round Table

Dear Mr. Klein:

By letter dated February 1, 1988, the American Heart Association submitted to the Antitrust Division of the Department of Justice a business review letter with regard to the proposed Pharmaceutical Round Table ("PRT"), of which the American Heart Association is a founding member. A favorable response was made by your division to this request by letter dated April 28, 1989. Copies of these two letters as well as a May 3, 1989 Department of Justice Release are attached hereto for your reference.

The purpose of this letter is to make a further business review request regarding proposed changes to the previously reviewed PRT in accordance with 28 C.F.R. Subsection 50.6 of the Code of Federal Regulations of the U.S. Department of Justice. The new PRT programs are scheduled to begin January 1998.

The PRT is a consortium of pharmaceutical companies that provides funds to the AHA for basic biomedical research by independent researchers relating broadly to the causes, prevention and treatment of cardiovascular diseases, including stroke. PRT members provide information about cardiovascular research awareness and collaborate on programs that reach the healthcare professional and consumer audiences. The AHA has decided to make certain changes in the PRT because of changes in the pharmaceutical industry and the changing needs of the AHA.

Chairman of the Board

Marilyn Hunn

President

Martha N. Hill, R.N., Ph.D.

Chairman-Elect

Edward F. Hines, Jr., Esq.

President-Elect

Valentin Fuster, M.D., Ph.D.

Immediate Past

Chairman of the Board

David A. Ness

Immediate Past President

Jan L. Breslow, M.D.

Secretary

Henry Morris, Jr., Esq.

Treasurer

Mack S. Linebaugh, Jr.

Vice Presidents

Hugh D. Allen, M.D.

C. William Balke, M.D.

William R.H. Broome, Esq.

Joy S. Frank, Ph.D.

Donald W. LaVan, M.D.

Janet Masson, B.S.N./FNP/PA-C

Lorne Peterson, R.N.

Lawrence B. Sidwin

Joan Ware, R.N., M.S.P.H.

Chairperson, Advocacy

Coordinating Committee

J. Walter Sinclair, Esq.

Chairperson, Marketing and

Communications Coordinating

Committee

John W. (Jack) Bates

Chairperson, Scientific

Publishing Committee

Elizabeth G. Nabel, M.D.

Chairperson, Scientific Sessions

Program Committee

Rose Marie Robertson, M.D.

Members-At-Large

R. Wayne Alexander, M.D., Ph.D.

Claire M. Bassett

William J. Bryant, Esq.

Vincent J. Bufalino, M.D.

Louis L. Cregler, M.D.

Charles Dennis, M.D.

Ann E. McPartlin

Nancy Houston Miller, R.N.

J.E. Chavez Paisley

Lynn A. Smaha, M.D., Ph.D.

Henry M. Sondheimer, M.D.

Janet O. South

Donald A. Trimble, C.P.A.

Jessie G. Wright, M.S., R.D., L.D.

Executive Vice President

Dudley H. Hafner

Senior Vice President

Corporate Operations

Walter D. Bristol, Jr.

Senior Vice President

Marketing

Jo A. Diehl

Senior Vice President

Communications and

Public Advocacy

Brigid McHugh Sanner

Senior Vice President

Science and Medicine

Rodman D. Starke, M.D.

Senior Vice President

Field Operations

M. Cass Wheeler

Vice President,

Corporate Secretary and Counsel

David Wm. Livingston, Esq.

The original seven founding members of PRT were Ciba-Geigy, Bristol-Myers, Sandoz, Squibb, Winthrop Pharmaceuticals, Wyeth-Ayerst and Genentech, Inc. Boehringer-Ingelheim was a regular member. The current members of the PRT are Astra Merck Inc., Bristol-Myers Squibb, Genentech, Inc., Parke-Davis, Pfizer, Inc., Sanofi Pharmaceuticals, Inc. and Wyeth-Ayerst Laboratories.

The proposed changes to the PRT involved are described below:

1. The amount each member will contribute to the PRT will be increased from (200,000 or )300,000 annually over a five year period (totaling $1,000,000 or $1,500,000) to $1,000,000 annually for a three year commitment, totaling $3,000,000.

2. All money has heretofore been used to fund research approved by the AHA. With the proposed changes, sixty percent (60%) of the contributed funds will be used as follows: half for targeted research and half for the funding of AHA approved research grants. The targeted research programs include areas of behavioral science, epidemiology and health services as they relate to the management of risk factors for primary and secondary prevention of cardiovascular disease and stroke. These target research programs will have a peer review process separate from the system of reviewing AHA research applications. Peer reviewers will be recruited from the body of experts from prominent institutions who have experience in the targeted science-based subject areas. The remaining forty percent (40%) of contributed money will fund educational programs. All money will continue to be carefully controlled and budgeted by AHA. Research grant applications will continue to be closely examined by impartial peer review committees whose members are experts in medical and scientific fields.

3. The existing PRT logo will be revised, with either a stacked or side-by-side layout. A copy of the proposed new PRT logo with both layouts along with the proposed revised Graphic Guidelines for Consumer Brands and Pharmaceutical Companies is attached for your reference. PRT members may use the logo in corporate promotional (not product) advertising.

Other than the proposed changes set forth above, the purpose and structure of the PRT as set forth in the 1988 business review request and your response of April 28, 1989 remain the same.

Page 3

The documents listed at the close of this letter or referred to herein are included for your reference with regard to this business review request. Should additional information or documents be required in order for a response to be made to this request, please do not hesitate to contact me.

With regards,

David Wm. Livingston

Vice President, Corporate Secretary & Counsel

Enclosures: Copy of February 1, 1988 Business Review Letter

Copy of April 28, 1989 Department of Justice Response Letter

Copy of May 3, 1989 Release of Department of Justice

Proposed new PRT logo

Proposed Graphic Standards for proposed new PRT logo